Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mefenamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.71 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.71 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | DHFR | P00374 | 1/20 | 0.71 |
| ▸ | MPO | P05164 | 1/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.71 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.71 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.71 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mefenamic Acid SCHEMBL10503020 | 0.97 | PTGS2 (0.71) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL16179953 | 0.97 | PTGS2 (0.71) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL11788882 | 0.89 | PTGS2 (0.58) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL11788892 | 0.87 | PTGS2 (0.56) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL27722088 | 0.83 | LMNA (0.74) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL7925344 | 0.83 | PTGS2 (0.76) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL29355128 | 0.83 | PTGS2 (1.00) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL29465887 | 0.83 | PTGS2 (1.00) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL29350572 | 0.83 | PTGS2 (1.00) | PTGS2LMNAMEN1KMT2ACYP1A2 | |
| Mefenamic Acid SCHEMBL3544 | 0.83 | PTGS2 (1.00) | PTGS2LMNAMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2596794-B1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | TETS GEORGY VIKTOROVICH (RU) | 2019-08-07 | — | — | EP | disclosed |
| US-10052327-B2 | Method for treating liver diseases of various origins | VIKTOR VENIAMINOVICH TETS (RU) | 2018-08-21 | — | — | US | disclosed |
| US-20180021339-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | Tets, Viktor Veniaminovich (RU) | 2018-01-25 | — | — | US | disclosed |
| US-9730933-B2 | Method for treating liver diseases of various origins | VIKTOR VENIAMINOVICH TETS (RU) | 2017-08-15 | — | — | US | disclosed |
| US-20160250214-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | Tets, Viktor Veniaminovich (RU) | 2016-09-01 | — | — | US | disclosed |
| US-20150158825-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | TETS, VIKTOR VENIAMINOVICH (RU) | 2015-06-11 | — | — | US | disclosed |
| US-8962640-B2 | Method for treating liver diseases of various origins | TETS, VIKTOR VENIAMINOVICH (RU) | 2015-02-24 | — | — | US | disclosed |
| EP-2596794-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | TETS, Georgy Viktorovich (RU) | 2013-05-29 | — | — | EP | disclosed |
| US-20120157483-A1 | Method for Treating Liver Diseases of Various Origins | TETS, VIKTOR VENIAMINOVICH (RU) | 2012-06-21 | — | — | US | disclosed |
| US-3988333-A | Tri-substituted aluminum salts or di-substituted aluminum salts of carboxyl group-containing, pharmaceutically effective compounds | TEIKOKU HORMONE MFG. CO., LTD. (JA) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250214-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | PYGL, IFNG, EIF2AK2 | PTGS2 348/4885PTGS1 404/4885LMNA 1578/4885 |
| US-20150158825-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | PYGL, IFNG, EIF2AK2 | PTGS2 348/4885PTGS1 404/4885LMNA 1578/4885 |
| US-10052327-B2 | Method for treating liver diseases of various origins | PYGL, IFNG, EIF2AK2 | PTGS2 348/4885PTGS1 404/4885LMNA 1578/4885 |
| US-20180021339-A1 | METHOD FOR TREATING LIVER DISEASES OF VARIOUS ORIGINS | PYGL, IFNG, EIF2AK2 | PTGS2 348/4885PTGS1 404/4885LMNA 1578/4885 |
| US-20120157483-A1 | Method for Treating Liver Diseases of Various Origins | PYGL, IFNG, EIF2AK2 | PTGS2 329/4885PTGS1 375/4885LMNA 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.